Rubius Therapeutics, Inc. - 10-K filing on 2022-02-25

Leases (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of minimum lease payments under the Company's operating leases

As of December 31, 2021, minimum lease payments under the Company’s operating leases are as follows (in thousands):


Year ending December 31,
2022	$	9,015
2023		7,447
2024		7,601
2025		7,818
2026		8,041
Thereafter		6,199
		46,121
Less: imputed interest		(8,815)
	$	37,306

Schedule of lease cost and lease liabilities for the Company's lease portfolio

The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows (in thousands, except term and discount rate amounts):


	Year ended December 31,
	2021		2020		2019
Lease cost:
Operating lease cost	$	8,173	$	9,240	$	7,208
Short-term lease cost		41		24		127
Variable lease cost		3,723		1,916		1,976
Sublease income		(719)		(1,017)		(908)
Total lease cost	$	11,218	$	10,163	$	8,403

Operating leases:
Operating lease, right-of-use-asset	$	35,095	$	40,447	$	46,559
Operating lease liabilities	$	9,015	$	8,945	$	10,540
Operating lease liabilities, net of current portion	$	28,291	$	32,762	$	36,867

Other information:
Weighted average remaining lease term - operating leases		5.8 years		6.70 years		7.47 years
Weighted-average discount rate - operating leases		7.60%		7.60%		7.58%